HIV-1 reverse transcriptase inhibitors remain a cornerstone of antiretroviral therapy, targeting the enzyme responsible for converting viral RNA into DNA. This class of drugs, particularly nucleoside ...

Purpose: The pharmacology, efficacy, and safety of etravirine and its clinical utility with respect to the available alternative human immunodeficiency virus (HIV) treatment options are reviewed.

† Drugs combined with NRTIs or NRTIs/NNRTIs are not listed. NNRTIs: Non-nucleoside reverse-transcriptase inhibitors; NRTIs: Nucleos(t)ide analog reverse-transcriptase inhibitors. Drug-resistance amino ...

(HealthDay News) — For treatment-naive patients infected with HIV-1, three nonnucleoside reverse transcriptase inhibitor-sparing initial antiretroviral regimens can attain similarly high rates of ...

Many cancers exhibit high levels of the reverse transcriptase enzyme. Single-agent lamivudine, a reverse transcriptase inhibitor, stopped disease progression in over 25% of patients with fourth-line ...

In July 2000, a 58-year-old man infected with the human immunodeficiency virus (HIV) began treatment with highly active antiretroviral therapy, which initially consisted of zidovudine, lamivudine, and ...

Switching to integrase strand transfer inhibitors (INSTI) from protease inhibitors is associated with new diabetes risk in people with HIV, according to a stu ...

Diabetes mellitus affects more than 10% of people with HIV, and its incidence is rising as the population ages, according to the National Institutes of Health. Antiretroviral therapies that treat HIV ...

The Aicardi–Goutières syndrome is a genetic encephalopathy that is associated with childhood illness and death. The syndrome is hypothesized to be due to misidentification of self-derived nucleic ...

HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...